IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
NCT06092892
This study is recruiting at 3 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective, single arm phase II clinical trial. Patients will be screened and enrolled per eligibility criteria. Patient, tumor, and treatment data will be documented.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
- Axillary Nodal Disease
- Female Breast Cancer
- Axilla; Breast
- Mastectomy; Lymphedema
- Tumor, Breast
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 45 years and older
- Sex
- Female
- Healthy volunteers
- Not accepted
- Sponsor
- Alice Chung
- Last updated on ClinicalTrials.gov
- August 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute · Los Angeles, CA
- CS Cancer at Huntington Cancer Center · Pasadena, CA
- CS Cancer at Valley Oncology Medical Group · Tarzana, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.